kinase, has demonstrated antitumor activity in acute myeloid leukaemia (AML) cell lines (Gürtler 58 et al, 2010a; Gürtler et al, 2010b; Mross et al, 2016; Tontsch-Grunt et al, 2010). Here we report 59 a phase I trial that evaluated the maximum tolerated dose (MTD), safety, efficacy and 60 pharmacokinetics (PK) of BI 811283 with low-dose cytarabine (LDAC) in patients with AML 61 considered ineligible for intensive treatment (NCT00632749). 62
6
Best overall response is presented in Table SIII . In Schedule A, two patients (7·1%) 103 achieved a complete remission (CR); 10 patients (35·7%) had no change as their best 104 response, 11 (39·3%) had progressive disease and for five patients (17·9%) no response 105 assessment was available. In Schedule B, five patients (13.9%) achieved a CR. Additionally, 106 one patient (2·8%) had a CR with incomplete haematologic recovery (CRi) and one further 107 patient (2·8%) had a partial remission (PR). Seventeen remaining patients (47·2%) had no 108 change, eight patients (22·2%) had progressive disease and for four patients (11·1%) no 109 response assessment was available. In Schedule A, both patients who achieved CR had 110 previously untreated AML, and in Schedule B, all but one patient who achieved CR, CRi or PR 111 had previously untreated AML. No dose-related trend in response rate was observed and 112 responses occurred after a median of 1 cycle of therapy (range, 1-7). For the eight patients 113 overall who had a best response of CR or CRi, the median remission duration was 263 days 114 (range, 15-1492) . 115 BI 811283 plasma PK profiles suggested no effect of the dosing schedule on the PK of 116 BI 811283, and in both treatment schedules, suggested close to dose-proportional PK (Fig S1) . 117
Cytarabine plasma concentration profiles were similar in each BI 811283 dose group (Fig S2) 
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Data S1. Methods
Patients
Adult patients with a confirmed diagnosis of AML according to the World Health Organization definition (excluding acute promyelocytic leukaemia) with previously untreated (except hydroxyurea) or relapsed/refractory disease and considered unsuitable for intensive induction or salvage therapy, were eligible for this study.
Inclusion criteria also included life expectancy of ≥3 months and an Eastern Cooperative
Oncology Group performance score ≤2, and patients were required to be eligible for low-dose 
Study design
15
The primary endpoint was to determine the MTD of two BI 811283 schedules in combination with LDAC based on the incidence of DLTs. Further endpoints included incidence and intensity of AEs, PK of cytarabine with BI 811283, and response. Genetic risk group was assessed according to published criteria (Döhner et al, 2010) .
Patients were randomized to one of two schedules combining BI 811283 (24-hour intravenous infusion) with LDAC (20 mg twice daily subcutaneously, days 1-10 of a 4-week cycle). In Schedule A, patients received BI 811283 on days 1 and 15 of a 4-week cycle. In Schedule B, patients received BI 811283 on day 1 of a 4-week cycle. Dose escalation was conducted for each schedule following a 3+3 design. The starting BI 811283 dose was 5 mg.
After the 5 mg dose cohorts, the protocol was amended to escalate the BI 811283 doses to approximately half the highest dose that was considered safe in a concurrent BI 811283 monotherapy trial conducted in solid tumours (Mross et al, 2016) . Accordingly, the second dose 
Criteria for therapy continuation
At the end of each treatment cycle, the response to treatment was assessed. To continue treatment with further cycles, the following criteria had to be met: absence of disease progression, neutrophils ≥500/μL (0·5 × 10 9 /L) and platelets ≥25,000/μL (25 × 10 9 /L), unless
Common Terminology Criteria for Adverse Events (CTCAE) grade 4 neutropenia or thrombocytopenia was pre-existing; and acceptable tolerability (in case of a dose-limiting toxicity
[DLT], patients could continue therapy only after recovery from DLT to CTCAE levels that would allow further therapy and only with a reduced dose).
Safety assessments
AEs were graded according to Common Terminology Criteria for Adverse Events version 3.0 recording date of onset, end date, treatment/action required and outcome. Safety laboratory examinations included haematology, biochemistry and coagulation parameters. A 12-lead resting electrocardiogram was performed at screening and at end-of-treatment visits.
Efficacy assessments
Response was assessed in the peripheral blood and bone marrow at the end of each treatment cycle. In case of extramedullary manifestations of leukaemia, response assessment by imaging was used to complement the blood and bone marrow assessment. Responses were assessed according to published criteria (Döhner et al, 2010) .
Pharmacokinetics
Blood was collected at specified time points during the first treatment cycle to determine plasma concentrations of BI 811283 and cytarabine. BI 811283 base salt concentrations were determined by a validated high-performance liquid chromatography tandem mass spectrometry assay (Nuvisan GmbH, Neu-Ulm, Germany). Analysis of the plasma samples for cytarabine was conducted at SGS Cephac Europe, Saint-Benoît Cedex, France.
Statistical analysis
All analyses were descriptive and exploratory by nature. 
